Accurate Education: 

Visual Snow Syndrome

A Physician’s Primer

Visual Snow Syndrome (VSS) is a neurological condition where individuals constantly see tiny, flickering dots, static, or flashing lights across their entire field of vision. Often likened to a untuned television screen, the static persists 24/7—even with eyes closed—and causes significant visual and non-visual disruptions.

 

See:  

  

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Visual Snow Syndrome:

A Physician’s Primer

 

 

What Is Visual Snow Syndrome?

Visual snow syndrome (VSS) is a neurological disorder characterized by the continuous perception of countless small, flickering dots throughout the entire visual field. Patients typically describe it as seeing “TV static” or the noise of a detuned analog television. The visual disturbance is persistent (not episodic), present in all lighting conditions, and affects the entire visual field.

VSS was first described in case reports in 1995 and has gained increasing recognition over the past decade. Proposed diagnostic criteria have been adopted into the appendix of the International Classification of Headache Disorders (ICHD-3).

—

Diagnostic Criteria

A diagnosis of visual snow syndrome requires all of the following:

1. Dynamic, continuous, tiny dots in the entire visual field, persisting for more than 3 months.

2. At least two of the following additional visual symptoms:

  • Palinopsia — afterimages (continued perception of an image after it has been removed) or trailing of moving objects
  • Enhanced entoptic phenomena — excessive floaters, self-light of the eye (phosphenes in darkness), blue field entoptic phenomenon (tiny bright dots seen against a blue sky)
  • Photophobia — light sensitivity
  • Nyctalopia — impaired night vision

3. Symptoms are not consistent with typical migraine visual aura (i.e., no scintillating scotoma or zig-zag lines).

4. Symptoms are not better explained by another disorder (e.g., retinal pathology, lesions in the visual pathway, occipital epilepsy, or drug effects).

Important: “Visual snow” as an isolated symptom is distinct from “visual snow syndrome,” which requires the additional associated symptoms listed above.

—

Epidemiology

  • Prevalence estimates are limited but suggest VSS affects approximately 2–3% of the general population based on population-based surveys, though many cases go unrecognized.
  • VSS can begin at any age; many patients report symptoms since childhood, while others develop them in adulthood.
  • There is no clear sex predominance in most studies.

Pathophysiology

The pathophysiology of VSS remains incompletely understood, but converging evidence points to a central neurological disorder rather than an ophthalmologic one:

  • Cortical hyperexcitability: Electrophysiological studies demonstrate hyperresponsivity in primary and secondary visual cortical areas.
  • Neuroimaging findings: Studies have identified hypermetabolism of the lingual gyrus, increased gray matter volume in various brain regions, and altered functional connectivity in visual pathways and thalamocortical networks.
  • Network disorder: Increasing evidence suggests VSS involves dysfunction in attention/salience networks and thalamocortical circuits, extending beyond the visual system alone.
  • Neurotransmitter involvement: Research has implicated glutamatergic dysregulation and serotonergic dysfunction, with impaired top-down inhibitory feedback mechanisms.

VSS is now considered a distinct entity from migraine aura, despite their frequent co-occurrence. The visual disturbance in VSS is persistent and does not fluctuate with the migraine cycle, and it does not respond to standard migraine preventive therapies.

Comorbidities

Clinicians should be aware of the high prevalence of comorbid conditions:

  • Migraine — present in approximately 50% of VSS patients, particularly migraine with aura
  • Tinnitus — reported in approximately 50% of patients
  • Depression — lifetime prevalence of ~40% in clinic-based cohorts
  • Anxiety — lifetime prevalence of ~45% in clinic-based cohorts
  • Other perceptual disorders — VSS may co-occur with persistent postural-perceptual dizziness (PPPD) and fibromyalgia, suggesting a possible spectrum of central sensory processing disorders

Screening for depression and anxiety is recommended in all patients with VSS.

Differential Diagnosis and Workup

Because VSS is a diagnosis of exclusion, secondary causes of pan-field visual disturbances must be ruled out:

Secondary causes to consider:

  • Retinal pathology (e.g., retinitis pigmentosa, uveitis)
  • Lesions in the visual pathway (optic nerve, chiasm, or cortical)
  • Occipital epilepsy
  • Idiopathic intracranial hypertension
  • Post-concussion syndrome
  • Hallucinogen persisting perception disorder (HPPD)
  • Medication-induced visual disturbances (certain antidepressants, recreational drugs, alcohol)
  • Post-infectious etiologies
  • Posterior cortical atrophy (rare)

Recommended workup:

  • Comprehensive ophthalmologic examination (including dilated fundoscopy and OCT if indicated)
  • Neurological examination
  • Brain MRI to exclude structural lesions
  • Consider EEG if occipital epilepsy is suspected
  • Detailed medication and substance use history
  • Screening for migraine, depression, anxiety, and tinnitus

Prognosis

  • VSS is typically a benign, non-progressive condition.
  • However, it can be significantly distressing and may substantially impair quality of life.
  • Patients with VSS attributed to an identifiable inciting event (e.g., concussion, infection, medication) may have a better prognosis than those with spontaneous onset.
  • Complete spontaneous remission is uncommon.

Management

There is currently no FDA-approved treatment for VSS, and no therapy reliably produces complete remission. Management is largely supportive and symptom-directed.

Pharmacotherapy

  • Lamotrigine is the most studied medication; partial improvement has been reported in approximately 19–62% of patients depending on the study, though complete remission is rare. A minimum dose of 100 mg BID has been suggested for adequate trials.
  • Benzodiazepines have shown symptom improvement in some case series (up to 71% partial improvement), but long-term use carries well-known risks.
  • Other medications (valproate, topiramate, acetazolamide, flunarizine) have been tried with limited or no benefit in most cases.
  • Caution: Certain antidepressants and other medications may worsen or trigger visual snow symptoms.

Non-Pharmacological Approaches

  • FL-41 tinted lenses / chromatic filters — consistently reported to provide symptomatic relief, particularly for photophobia
  • Cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy — emerging evidence supports benefit in coping and symptom management
  • Neuro-optometric visual rehabilitation therapy (NORT) — under investigation
  • Repetitive transcranial magnetic stimulation (rTMS) — early-stage research, not yet standard of care

General Counseling

  • Reassurance that VSS is a recognized neurological condition and is typically non-progressive
  • Validation of the patient’s experience — many patients have been told their symptoms are not real
  • Avoidance of known exacerbating factors (alcohol, recreational drugs, certain medications)
  • Referral to neurology (preferably neuro-ophthalmology or headache specialist) for patients with significant functional impairment

Key Takeaways

1. VSS is a distinct neurological syndrome — not a variant of migraine aura, not a psychiatric condition, and not an ophthalmologic disease.

2. Diagnosis requires persistent visual static plus at least two additional visual symptoms, after exclusion of secondary causes.

3. Pathophysiology involves cortical hyperexcitability and network dysfunction, not retinal or optic nerve disease.

4. Comorbid migraine, tinnitus, depression, and anxiety are common and should be screened for.

5. Treatment is limited; lamotrigine and FL-41 tinted lenses have the most evidence, though responses are partial.

6. Patient validation and reassurance are critical components of care.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.